Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ademetionine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.81 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.81 |
| ▸ | PCMT1 | P22061 | 3/20 | 0.81 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.81 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.81 |
| ▸ | NSD3 | Q9BZ95 | 2/20 | 0.81 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | PNMT | P11086 | 1/20 | 0.81 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.81 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.81 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.81 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.81 |
| ▸ | AMD1 | P17707 | 6/20 | 0.71 |
| ▸ | FASN | P49327 | 1/20 | 0.54 |
| ▸ | NSD2 | O96028 | 2/20 | 0.53 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.53 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.53 |
| ▸ | NNMT | P40261 | 2/20 | 0.53 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ademetionine SCHEMBL3685223 | 0.99 | CARM1 (0.83) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL10400453 | 0.96 | CARM1 (0.77) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL1228179 | 0.96 | CARM1 (0.77) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL31536258 | 0.94 | AMD1 (0.78) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL1300205 | 0.90 | CARM1 (1.00) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL29355793 | 0.90 | CARM1 (1.00) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL25176 | 0.90 | CARM1 (1.00) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL1300198 | 0.90 | CARM1 (1.00) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL4747876 | 0.90 | CARM1 (0.98) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL1980696 | 0.90 | CARM1 (0.98) | CARM1PCMT1PRMT5PRMT1NSD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6759395-B2 | ENTERIC COATINGS | ORCHID CHEMICALS & PHARMACEUTICALS, LTD. (IN) | 2004-07-06 | — | — | US | claimed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | ASCENDIS PHARMA A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| EP-3782649-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2021-02-24 | — | — | EP | disclosed |
| EP-2459220-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2020-09-09 | — | — | EP | disclosed |
| US-20130053301-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| WO-2013024048-A1 | POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024053-A1 | CARRIER-LINKED PRODRUGS HAVING REVERSIBLE CARBOXYLIC ESTER LINKAGES | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024047-A1 | HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024049-A1 | PROTEIN CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| EP-2459220-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011089216-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| US-6635615-B1 | Stable salts of S-adenosyl-l-methionine | HEBERT SAM-E LLC | 2003-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | KDR 143/4885CARM1 2047/4885PCMT1 189/4885 |
| US-20130053301-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | DNPEP, PEPD, DAO | KDR 894/4885CARM1 1246/4885PCMT1 86/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | KDR 143/4885CARM1 2047/4885PCMT1 189/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | KDR 2030/4885CARM1 2107/4885PCMT1 1934/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | KDR 143/4885CARM1 2047/4885PCMT1 189/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | KDR 2030/4885CARM1 2107/4885PCMT1 1934/4885 |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | PTMS, PGLS, PAM | KDR 1421/4885CARM1 1987/4885PCMT1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.